ClinicalTrials.gg
CompletedNCT00128934Updated Dec 27, 2007

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

A Phase 3 interventional study of levonorgestrel/ethinyl estradiol in Menstruation Disturbances and Premenstrual Syndrome, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 83 sites in 2 countries. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2007-12-27.

Primary conditionPremenstrual SyndromeRegistry: Menstruation DisturbancesReclassifiedWhy we changed it
Registry
Menstruation Disturbances — the first condition term the registry derived for this study.
ClinicalTrials.gg
Premenstrual Syndrome
Why
  1. The study's listed conditions name Premenstrual Syndrome, a narrower term within Menstruation Disturbances.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
744
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Premenstrual Syndrome with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Premenstrual Syndrome · United States.

Planned enrollment
Largest of 31
744 · median 40
Started
2005
with 1 other
Phase 3
3 of 36
none open now
Registered
8th of 36
by date
Lead sponsor
2 of 36
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 36 studies in Premenstrual Syndrome with a site in United States, this one has the largest planned enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2005, is one of 3 in phase 3, and was the 8th registered.

Premenstrual Syndrome

177 studies on the registry are indexed under Premenstrual Syndrome; 32 are open to participants now.

Browse Premenstrual Syndrome studies →

Open to participants now

6 of the 36 studies in Premenstrual Syndrome with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Premenstrual Syndrome studies recruiting now, none (0%) set no upper age limit and 12 (100%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 49 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Premenstrual Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether levonorgestrel (LNG)/ethinyl estradiol (EE) is effective in treating the symptoms of severe premenstrual syndrome (PMS).

03

Conditions studied

  • Menstruation Disturbances
  • Premenstrual Syndrome

Browse trials for

Keywords

  • Premenstrual Syndrome (PMS)
  • Hormone Therapy
04

In context

Premenstrual Syndrome Reclassified

177 studies on the registry are indexed under Premenstrual Syndrome; 32 are open to participants now.

This study's planned enrollment of 744 is above the median of 70 across 154 interventional studies indexed under Premenstrual Syndrome.

Browse Premenstrual Syndrome studies →

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Compared within Premenstrual Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Menstruation Disturbances. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Generally healthy, women aged 18 to 49 years.
  • History of severe PMS symptoms over the last year, as determined by the investigator.
  • Regular 21 to 35 day menstrual cycle for 2 months prior to first study visit.

Exclusion criteria

Exclusion Criteria:

  • Major depressive disorder requiring antidepressant treatment or hospitalization within the last 3 years.
  • to combination oral .
  • Use of antidepressants/anxiolytics within 10 days of screening and for the duration of the study.

Other exclusions apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
744 participants (estimated)

Interventions

07

What researchers measure

Primary outcomes

  1. Mean change in average Daily Record of Severity of Problems (DRSP) 21-item total daily score

Secondary outcomes

  1. Change from baseline in DRSP 21-item daily score based on the 5 days with the highest DRSP scores in each "estimated" treatment cycle

08

Study locations

83 sites
  • Scottsdale, Arizona 85251, United States
  • Tucson, Arizona 85715, United States
  • Jonesboro, Arkansas 72401, United States
  • Little Rock, Arkansas 72205, United States
  • Carmichael, California 95608, United States
  • Los Angeles, California 90095, United States
  • San Diego, California 92103, United States
  • Denver, Colorado 80202, United States
  • Lakewood, Colorado 80228, United States
  • Longmont, Colorado 80501, United States
  • Middletown, Connecticut 06457, United States
  • New Haven, Connecticut 06510, United States
  • Waterbury, Connecticut 06708, United States
  • Washington, District of Columbia 20037, United States
  • Adventure, Florida 33180, United States
  • Clearwater, Florida 33761, United States
  • Fort Myers, Florida 33916, United States
  • Hialeah, Florida 33016, United States
  • Pembroke Pines, Florida 33024, United States
  • West Palm Beach, Florida 33407, United States
  • Atlanta, Georgia 30328, United States
  • Atlanta, Georgia 30342, United States
  • Savannah, Georgia 31406, United States
  • Boise, Idaho 83712, United States
  • Chicago, Illinois 60631, United States
  • Chicago, Illinois 60634, United States
  • Evansville, Indiana 47714, United States
  • South Bend, Indiana 46601, United States
  • Lexington, Kentucky 40509, United States
  • New Orleans, Louisiana 70114, United States
  • Glen Burnie, Maryland 21061, United States
  • Boston, Massachusetts 02114, United States
  • Pittsfield, Massachusetts 01201, United States
  • Springfield, Massachusetts 01107, United States
  • Brooklyn, New York 11235, United States
  • Buffalo, New York 14214, United States
  • New York City, New York 10021, United States
  • Rochester, New York 14609, United States
  • Fayetteville, North Carolina 28304, United States
  • New Bern, North Carolina 28562, United States
  • Winston-Salem, North Carolina 27103, United States
  • Cincinnati, Ohio 45219, United States
  • Cleveland, Ohio 44122, United States
  • Mogadore, Ohio 44260, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Tulsa, Oklahoma 74135, United States
  • Eugene, Oregon 97401, United States
  • Medford, Oregon 97504, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Philadelphia, Pennsylvania 19114, United States
  • Wexford, Pennsylvania 15090, United States
  • East Providence, Rhode Island 02914, United States
  • Greer, South Carolina 29654, United States
  • Hilton Head Island, South Carolina 29926, United States
  • Nashville, Tennessee 37203, United States
  • Austin, Texas 78756, United States
  • Carrollton, Texas 75010, United States
  • Conroe, Texas 77304, United States
  • San Antonio, Texas 78229, United States
  • Salt Lake City, Utah 84107, United States
  • Sandy, Utah 84070, United States
  • Burlington, Vermont 05401, United States
  • Charlottesville, Virginia 22903, United States
  • Norfolk, Virginia 23502, United States
  • Richmond, Virginia 23230, United States
  • Richmond, Virginia 23233, United States
  • Richmond, Virginia 23294, United States
  • Lakewood, Washington 98499, United States
  • Renton, Washington 98055, United States
  • Edmonton, Alberta T6G 2C8, Canada
  • Edmonton, Alberta T6L 5X8, Canada
  • Kelowna, British Columbia V1Y 2H4, Canada
  • Vancouver, British Columbia V6H 3N1, Canada
  • Hamilton, Ontario L8N 4A6, Canada
  • Toronto, Ontario M9W 4L6, Canada
  • Hull, Quebec J9A 1K7, Canada
  • Montréal, Quebec H1T 1P6, Canada
  • Montréal, Quebec H3A 1A1, Canada
  • Pointe-Claire, Quebec H9R 4S3, Canada
  • Quebec City, Quebec G1R 2W8, Canada
  • Quebec City, Quebec G1S 2L6, Canada
  • Shawinigan, Quebec G9N 2H6, Canada
  • Sherbrooke, Quebec J1H 4J6, Canada
09

References and documents

Publications

  • Halbreich U, Freeman EW, Rapkin AJ, Cohen LS, Grubb GS, Bergeron R, Smith L, Mirkin S, Constantine GD. Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder. Contraception. 2012 Jan;85(1):19-27. doi: 10.1016/j.contraception.2011.05.008. Epub 2011 Jul 13. PubMed 22067793 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2005
First posted
Aug 10, 2005
Start
Aug 2005
CompletionActual
Dec 2007
Last update
Dec 27, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00128934
First posted
Aug 10, 2005
Start date
Aug 2005
Completion
Dec 2007
Last update
Dec 27, 2007

Study contacts

Medical Monitor, MD
study director · Wyeth is now a wholly owned subsidiary of Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levonorgestrel · Ethinyl Estradiol

Start the discussion